For the Inventor, By the Inventor

Enter assignee name

Durham, NC, United States of America

Precision Biosciences, Inc.

USPTO Granted Patents = 48

EPO Patents = 40

Trademarks = 4

Forward Citations = 270

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

James Jefferson Smith (40 out of 60 patents)

Derek Jantz (38 out of 56 patents)

Victor Bartsevich (18 out of 18 patents)

4. Michael G Nicholson (17 out of 18 patents)

5. Daniel T MacLeod (14 out of 14 patents)

6. Jeyaraj Antony (12 out of 12 patents)

7. Aaron Martin (8 out of 8 patents)

8. Janel Lape (8 out of 8 patents)

9. Jon E Chatterton (5 out of 5 patents)

10. Clayton Beard (4 out of 4 patents)

11. John K Morris (4 out of 35 patents)

12. Hui Li (3 out of 3 patents)

13. Michelle Brenda Pires (3 out of 3 patents)

14. Caitlin Turner (3 out of 3 patents)

15. Gary Owens (3 out of 3 patents)

48 patents: Sort by Forward Citations

1. 12448613 - Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene (2025-10-21),

2. 12410418 - Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome (2025-09-09),

3. 12351839 - Rationally-designed single-chain meganucleases with non-palindromic recognition sequences (2025-07-08),

4. 12006522 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-06-11),

5. 11993793 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-05-28),

6. 11866747 - Engineered meganucleases that target human mitochondrial genomes (2024-01-09),

7. 11851680 - Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) (2023-12-26),

8. 11788077 - Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome (2023-10-17),

9. 11786554 - Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene (2023-10-17),

10. 11753630 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2023-09-12),

11. 11680254 - Engineered meganucleases specific for recognition sequences in the PCSK9 gene (2023-06-20),

12. 11453861 - Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) (2022-09-27),

13. 11384335 - Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) (2022-07-12),

14. 11286291 - Co-stimulatory domains for use in genetically-modified cells (2022-03-29),

15. 11278632 - Engineered nucleases useful for treatment of hemophilia A (2022-03-22),

Precision BioSciences, Inc. is a biotechnology company that develops gene editing and cell therapy technologies. Their innovative platform, ARCUS, enables the precise modification of genes in living cells. By harnessing the power of ARCUS, Precision BioSciences aims to address a wide range of genetic diseases and advance the development of new therapies. The company is committed to providing safe and effective solutions for patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

48 Patents

#22 in Durham, NC

#168 in North Carolina

#7,024 in US

#14,104 in the World

Durham, NC, United States of America

Precision Biosciences, Inc.

Forward Citations = 270

26 inventors:

James Jefferson Smith (40 out of 60 patents)

Derek Jantz (38 out of 56 patents)

Victor Bartsevich (18 out of 18 patents)

4. Michael G Nicholson (17 out of 18 patents)

5. Daniel T MacLeod (14 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…